jueves, 1 de agosto de 2019

BMC Cancer | Experimental therapeutics and drug development

BMC Cancer | Experimental therapeutics and drug development

BMC Cancer



Experimental therapeutics and drug development

This section covers all aspects of preclinical investigations on therapeutic agents. It welcomes submissions concerning anti-cancer drug discovery and development, and targeted therapies.
Page 1 of 10
  1. Content Type:Research Article

    Genipin is a compound derived from gardenia fruit extract. Although Genipin has anti-tumor effects in various cancers, its effect and mechanism in gastric cancer remain unclear. Here, we investigated the relat...
    Authors:Min Jee Jo, Soyeon Jeong, Hye Kyeong Yun, Dae Yeong Kim, Bo Ram Kim, Jung Lim Kim, Yoo Jin Na, Seong Hye Park, Yoon A. Jeong, Bu Gyeom Kim, Hassan Ashktorab, Duane T. Smoot, Jun Young Heo, Jeongsu Han, Dae-Hee Lee and Sang Cheul Oh
    Citation:BMC Cancer 2019 19:739
    Published on: 
  2. Content Type:Research Article

    Soft tissue sarcoma (STS) comprises a family of rare, heterogeneous tumors of mesenchymal origin. Single-agent doxorubicin remains the first-line standard-of-care treatment for advanced and inoperable STS, but...
    Authors:Jasmien Cornillie, Agnieszka Wozniak, Britt Van Renterghem, Nathalie Van Winkel, Jasmien Wellens, Yemarshet K. Gebreyohannes, Maria Debiec-Rychter, Raf Sciot, Daphne Hompes and Patrick Schöffski
    Citation:BMC Cancer 2019 19:724
    Published on: 
  3. Content Type:Research Article

    Multiple myeloma (MM), characterized by cancerous proliferation of plasmablasts (PB) and plasma cells (PC), remains incurable in many patients. Differentially expressed molecules between MM PCs and healthy PCs...
    Authors:Ying Fang, Ruonan Xu, Bing Zhai, Chunmei Hou, Ning Ma, Liang Wang, Gencheng Han, Zhenyu Jiang and Renxi Wang
    Citation:BMC Cancer 2019 19:700
    Published on: 
  4. Content Type:Research Article

    While multiagent chemotherapy has dramatically improved the prognosis of sarcoma, the novel chemotherapeutics have hardly developed over the past 30 years. Caffeine can induce apoptosis, delays in cell cycle p...
    Authors:Kensaku Abe, Norio Yamamoto, Katsuhiro Hayashi, Akihiko Takeuchi and Hiroyuki Tsuchiya
    Citation:BMC Cancer 2019 19:689
    Published on: 
  5. Content Type:Research Article

    Metastasis is a leading cause of breast cancer mortality. The induction of epithelial-to-mesenchymal transition (EMT) and complex oncogenic signaling is a vital step in the evolution of highly metastatic and t...
    Authors:Jia-Hong Chen, Wen-Chien Huang, Oluwaseun Adebayo Bamodu, Peter Mu-Hsin Chang, Tsu-Yi Chao and Tse-Hung Huang
    Citation:BMC Cancer 2019 19:634
    Published on: 
  6. Content Type:Research Article

    Malignant pleural effusion (MPE) is a devastating sequela associated with cancer. Talc pleurodesis is a common treatment strategy for MPE but has been estimated to be unsuccessful in up to 20–50% of patients. ...
    Authors:Tim N. Beck, Alexander Y. Deneka, Louis Chai, Colin Kanach, Priya Johal, Nicolas J. Alvarez, Yanis Boumber, Erica A. Golemis and Glenn W. Laub
    Citation:BMC Cancer 2019 19:614
    Published on: 
  7. Content Type:Research Article

    Podoplanin (PDPN), a transmembrane O-glycoprotein, is up-regulated in many tumors and is involved in tumor metastasis and malignant progression. In previous studies, we generated a functional blocking monoclonal ...
    Authors:Mengqiao Xu, Xia Wang, Yanfang Pan, Xingpeng Zhao, Bin Yan, Changgeng Ruan, Lijun Xia and Yiming Zhao
    Citation:BMC Cancer 2019 19:599
    Published on: 
  8. Content Type:Study Protocol

    Thyroid cancer is the most common endocrine malignancy. Some advanced disease is, or becomes, resistant to radioactive iodine therapy (refractory disease); this holds poor prognosis of 10% 10-year overall surv...
    Authors:Sarah R. Brown, Andrew Hall, Hannah L. Buckley, Louise Flanagan, David Gonzalez de Castro, Kate Farnell, Laura Moss, Rebecca Gregory, Kate Newbold, Yong Du, Glenn Flux and Jonathan Wadsley
    Citation:BMC Cancer 2019 19:582
    Published on: 
  9. Content Type:Research Article

    Molecular markers predicting survival in esophageal adenocarcinoma (EAC) are rare. Specifically, in favorable oncologic situations, e.g. nodal negativity or major neoadjuvant therapy response, there is a lack ...
    Authors:Lars M. Schiffmann, Heike Göbel, Heike Löser, Fabian Schorn, Jan Paul Werthenbach, Hans F. Fuchs, Patrick S. Plum, Marc Bludau, Thomas Zander, Wolfgang Schröder, Christiane J. Bruns, Hamid Kashkar, Alexander Quaas and Florian Gebauer
    Citation:BMC Cancer 2019 19:531
    Published on: 
  10. Content Type:Research Article

    The phase III EMILIA and TH3RESA trials demonstrated clinical benefits of trastuzumab emtansine (T-DM1) therapy in patients with previously treated HER2-positive metastatic breast cancer (MBC). Data from these...
    Authors:Edith A. Perez, Sanne Lysbet de Haas, Wolfgang Eiermann, Carlos H. Barrios, Masakazu Toi, Young-Hyuck Im, Pier Franco Conte, Miguel Martin, Tadeusz Pienkowski, Xavier B. Pivot, Howard A. Burris III, Sven Stanzel, Monika Patre and Paul Anthony Ellis
    Citation:BMC Cancer 2019 19:517
    Published on: 
    The Correction to this article has been published in BMC Cancer 2019 19:620
  11. Content Type:Research Article

    Adult T-cell leukemia/lymphoma (ATL) is a peripheral T-cell malignancy caused by long-term human T-cell leukemia virus type I (HTLV-1) infection. Survivin-responsive, conditionally replicating adenoviruses reg...
    Authors:Shinsuke Suzuki, Hiroki Kofune, Kimiharu Uozumi, Makoto Yoshimitsu, Naomichi Arima, Kenji Ishitsuka, Shin-ichi Ueno and Ken-ichiro Kosai
    Citation:BMC Cancer 2019 19:516
    Published on: 
  13. Content Type:Research Article

    Liposarcoma (LPS) is a tumor derived from adipose tissue, and has the highest incidence among soft tissue sarcomas. Dedifferentiated liposarcoma (DDLPS) is a malignant tumor with poor prognosis. Recurrence and...
    Authors:Eun Byeol Jo, Young Sang Lee, Hyunjoo Lee, Jae Berm Park, Hyojun Park, Yoon-La Choi, Doopyo Hong and Sung Joo Kim
    Citation:BMC Cancer 2019 19:496
    Published on: 
  14. Content Type:Study Protocol

    Testosterone suppression is the standard treatment for advanced prostate cancer, and it is associated with side-effects that impair patients’ quality of life, like sexual dysfunction, osteoporosis, weight gain...
    Authors:Gustavo Werutsky, Fernando Cotait Maluf, Eduardo Henrique Cronemberger, Vinicius Carrera Souza, Suelen Patricia dos Santos Martins, Fábio Peixoto, Oren Smaletz, Fábio Schutz, Daniel Herchenhorn, Telma Santos, Flavio Mavignier Carcano, David Queiroz Muniz, Paulo R. S. Nunes Filho, Facundo Zaffaroni, Carlos Barrios and André Fay
    Citation:BMC Cancer 2019 19:487
    Published on: 
  16. Content Type:Study Protocol

    While recent years have seen a revolution in the treatment of metastatic cutaneous melanoma, no treatment has yet been able to demonstrate any prolonged survival in metastatic uveal melanoma. Thus, metastatic ...
    Authors:Henrik Jespersen, Roger Olofsson Bagge, Gustav Ullenhag, Ana Carneiro, Hildur Helgadottir, Ingrid Ljuslinder, Max Levin, Charlotta All-Eriksson, Bengt Andersson, Ulrika Stierner, Lisa M. Nilsson, Jonas A. Nilsson and Lars Ny
    Citation:BMC Cancer 2019 19:415
    Published on: 
  17. Content Type:Technical Advance

    Previous work in our laboratory demonstrated that antiprogestin mifepristone impairs the growth and adhesion of highly metastatic cancer cells, and causes changes in their cellular morphology. In this study, w...
    Authors:Sabrina J. Ritch, BreeAnn N. Brandhagen, Alicia A. Goyeneche and Carlos M. Telleria
    Citation:BMC Cancer 2019 19:376
    Published on: 
  18. Content Type:Research Article

    Head and neck squamous cell carcinoma (HNSCC) represents one of the most common malignancies worldwide with a high mortality rate mainly due to lack of early detection markers, frequent association with metast...
    Authors:Subhayan Sur, Hiroshi Nakanishi, Robert Steele and Ratna B. Ray
    Citation:BMC Cancer 2019 19:354
    Published on: 
  19. Content Type:Research Article

    Optimising breast cancer treatment remains a challenge. Resistance to therapy is a major problem in both ER- and ER+ breast cancer. Tumour recurrence after chemotherapy and/or targeted therapy leads to more ag...
    Authors:Lana McClements, Stephanie Annett, Anita Yakkundi, Martin O’Rourke, Andrea Valentine, Nermeen Moustafa, Abdelrahim Alqudah, Bruno M. Simões, Fiona Furlong, Amy Short, Stuart A. McIntosh, Helen O. McCarthy, Robert B. Clarke and Tracy Robson
    Citation:BMC Cancer 2019 19:351
    Published on: 
  20. Content Type:Research Article

    The exact signalling mechanism of the mTOR complex remains a subject of constant debate, even with some evidence that amino acids participate in the same pathway as used for insulin signalling during protein s...
    Authors:Bread Cruz, André Oliveira, Gislaine Ventrucci and Maria Cristina Cintra Gomes-Marcondes
    Citation:BMC Cancer 2019 19:349
    Published on: 
  21. Content Type:Research Article

    Most tumor cells show aberrantly activated Akt which leads to increased cell survival and resistance to cancer radiotherapy. Therefore, targeting Akt can be a promising strategy for radiosensitization. Here, w...
    Authors:Cholpon S. Djuzenova, Vanessa Fiedler, Simon Memmel, Astrid Katzer, Dmitri Sisario, Philippa K. Brosch, Alexander Göhrung, Svenja Frister, Heiko Zimmermann, Michael Flentje and Vladimir L. Sukhorukov
    Citation:BMC Cancer 2019 19:299
    Published on: 
  22. Content Type:Research Article

    With poor prognosis and limited treatment options for advanced hepatocellular carcinoma (HCC), development of novel therapeutic agents is urgently needed. This single-arm phase I study sought to assess the saf...
    Authors:Ying Fan, Shu Li, Xiaoyan Ding, Jian Yue, Jun Jiang, Hong Zhao, Rui Hao, Weiliang Qiu, Kezhen Liu, Ying Li, Shengdian Wang, Limin Zheng, Bin Ye, Kun Meng and Binghe Xu
    Citation:BMC Cancer 2019 19:279
    Published on: 
  23. Content Type:Research Article

    Codrituzumab, a humanized monoclonal antibody against Glypican-3 (GPC3), which is expressed in hepatocellular carcinoma (HCC), was tested in a randomized phase II trial in advanced HCC patients who had failed ...
    Authors:Melanie F. Pradier, Bernhard Reis, Lori Jukofsky, Francesca Milletti, Toshihiko Ohtomo, Fernando Perez-Cruz and Oscar Puig
    Citation:BMC Cancer 2019 19:278
    Published on: 
  24. Content Type:Research Article

    Recent advances in the treatment of melanoma that involve immunotherapy and B-Raf inhibition have revolutionised cancer care for this disease. However, an un-met clinical need remains in B-Raf inhibitor resist...
    Authors:Connor M. Blair, Nicola M. Walsh, Bruce H. Littman, Frank W. Marcoux and George S. Baillie
    Citation:BMC Cancer 2019 19:266
    Published on: 
  25. Content Type:Research Article

    Epithelial-mesenchymal transition (EMT) may be one of the reasons for the failure in some clinical trials regarding histone deacetylase inhibitors (HDACIs)-treated solid tumors. We investigated the effects of ...
    Authors:Zhihua Shen, Xiaomin Liao, Zhongming Shao, Muyin Feng, Jianling Yuan, Sisi Wang, Siyuan Gan, Yanping Ha, Zhiwei He and Wei Jie
    Citation:BMC Cancer 2019 19:262
    Published on: 
  26. Content Type:Research Article

    Garlic has been used for centuries for its flavour and health promoting properties that include protection against cancer. The vinyl disulfide-sulfoxide ajoene is one of the phytochemicals found in crushed clo...
    Authors:Catherine H. Kaschula, Rosanna Tuveri, Ellen Ngarande, Kevin Dzobo, Christopher Barnett, Daniel A. Kusza, Lisa M. Graham, Arieh A. Katz, Mohamed Suhail Rafudeen, M. Iqbal Parker, Roger Hunter and Georgia Schäfer
    Citation:BMC Cancer 2019 19:248
    Published on: 
  27. Content Type:Research Article

    High-risk neuroblastoma with N-Myc amplification remains a therapeutic challenge in paediatric oncology. Antagonism of pro-death Bcl-2 homology (BH) proteins to pro-survival BH members such as Mcl-1 and Bcl-2 ...
    Authors:Stefanie Klenke, Neval Akdeli, Patrick Stelmach, Lukas Heukamp, Johannes H. Schulte and Hagen S. Bachmann
    Citation:BMC Cancer 2019 19:243
    Published on: 
  28. Content Type:Case Report

    Patients with relapsed/refractory acute myeloid leukemia after hematopoietic stem cell transplantation (HSCT) have a poor prognosis, with a 2-year survival rate of 14%. The optimal treatment for these patients...
    Authors:Mengqi Jin, Yongxian Hu, Wenjun Wu, Yi Luo, Yamin Tan, Jian Yu, Aiyun Jin, Luxin Yang, He Huang and Guoqing Wei
    Citation:BMC Cancer 2019 19:242
    Published on: 
    The Correction to this article has been published in BMC Cancer 2019 19:486
  29. Content Type:Research Article

    The tumor suppressor protein phosphatase and tensin homolog (PTEN) is a key regulator of the PI3K/AKT pathway which is frequently altered in a variety of tumors including a subset of acute B-lymphoblastic leuk...
    Authors:Anna Richter, Catrin Roolf, Mohamed Hamed, Yvonne Saara Gladbach, Sina Sender, Christoph Konkolefski, Gudrun Knübel, Anett Sekora, Georg Fuellen, Brigitte Vollmar, Hugo Murua Escobar and Christian Junghanss
    Citation:BMC Cancer 2019 19:202
    Published on: 
  30. Content Type:Research Article

    Treatment options for advanced thyroid cancer refractory to standard therapies are limited. The safety and efficacy of pembrolizumab were evaluated in patients with advanced differentiated thyroid cancer expre...
    Authors:Janice M. Mehnert, Andrea Varga, Marcia S. Brose, Rahul R. Aggarwal, Chia-Chi Lin, Amy Prawira, Filippo de Braud, Kenji Tamura, Toshihiko Doi, Sarina A. Piha-Paul, Jill Gilbert, Sanatan Saraf, Pradeep Thanigaimani, Jonathan D. Cheng and Bhumsuk Keam
    Citation:BMC Cancer 2019 19:196
    Published on: 
  31. Content Type:Research Article

    It has been demonstrated that relatively small variations of the parameters of exposure to extremely low frequency magnetic fields (ELF-MF) can change significantly the outcome of experiments. Hence, either in...
    Authors:Leonardo Makinistian, Eva Marková and Igor Belyaev
    Citation:BMC Cancer 2019 19:188
    Published on: 
  32. Content Type:Research Article

    MicroRNAs are noncoding RNA molecules of ~ 22 nucleotides with diagnostic and therapeutic action [Curr Drug Targets, 2015. 16(12): p. 1381-403], affecting the expression of mRNAs involved in invasion, migratio...
    Authors:Olga D’Almeida, Omar Mothar, Esther Apraku Bondzie, Yolande Lieumo, Laure Tagne, Sumeet Gupta, Thomas Volkert, Stuart Levine and Jean-Bosco Tagne
    Citation:BMC Cancer 2019 19:136
    Published on: 
  33. Content Type:Research Article

    Treatment with recombinant human granulocyte-colony stimulating factor (G-CSF) is accepted standard for prevention of chemotherapy-induced neutropenia. RGB-02 (Gedeon Richter) is a proposed biosimilar to pegyl...
    Authors:Zsuzsanna Kahan, Daniela Grecea, Martin Smakal, Sergei Tjulandin, Igor Bondarenko, Luca Perjesi, Andras Illes, Karoly Horvat-Karajz and Ildiko Aradi
    Citation:BMC Cancer 2019 19:122
    Published on: 
  34. Content Type:Research Article

    Due to the lack of effective therapies and poor prognosis in TNBC (triple-negative breast cancer) patients, there is a strong need to develop effective novel targeted therapies for this subtype of breast cance...
    Authors:Nuramalina H. Mumin, Neele Drobnitzky, Agata Patel, Luiza Madia Lourenco, Fiona F. Cahill, Yanyan Jiang, Anthony Kong and Anderson J. Ryan
    Citation:BMC Cancer 2019 19:102
    Published on: 
  35. Content Type:Research Article

    Synthetic indolyl- pyridinyl- propenones (IPPs) induce methuosis, a form of non-apoptotic cell death, in glioblastoma and other cancer cell lines. Methuosis is characterized by accumulation of cytoplasmic vacu...
    Authors:Zehui Li, Nneka E. Mbah, Jean H. Overmeyer, Jeffrey G. Sarver, Sage George, Christopher J. Trabbic, Paul W. Erhardt and William A. Maltese
    Citation:BMC Cancer 2019 19:77
    Published on: 
  36. Content Type:Research Article

    To date, the cornerstone of treatment in patients with advanced or metastatic cholangiocarcinoma (CCA) is systemic chemotherapy based on a combination of gemcitabine and a platinum derivative. Other therapeuti...
    Authors:Markus Moehler, Annett Maderer, Anne Ehrlich, Friedrich Foerster, Arno Schad, Tanja Nickolay, Christian Ruckes, Arndt Weinmann, Visvakanth Sivanathan, Jens U. Marquardt, Peter Robert Galle, Marcus Woerns and Thomas Thomaidis
    Citation:BMC Cancer 2019 19:55
    Published on: 
  37. Content Type:Research Article

    Shikonin, a natural naphthoquinone, is abundant in Chinese herb medicine Zicao (purple gromwell) and has a wide range of biological activities, especially for cancer. Shikonin and its analogues have been repor...
    Authors:Shoude Zhang, Qiang Gao, Wei Li, Luwei Zhu, Qianhan Shang, Shuo Feng, Junmei Jia, Qiangqiang Jia, Shuo Shen and Zhanhai Su
    Citation:BMC Cancer 2019 19:20
    Published on: 
  38. Content Type:Research Article

    A prospective, randomised phase II study demonstrated clinical benefit of axitinib dose titration in a subset of treatment-naïve patients treated with axitinib for metastatic renal cell carcinoma. This analysi...
    Authors:Yoshihiko Tomita, Hirotsugu Uemura, Mototsugu Oya, Nobuo Shinohara, Tomonori Habuchi, Yosuke Fujii, Yoichi Kamei, Yoshiko Umeyama, Angel H. Bair and Brian I. Rini
    Citation:BMC Cancer 2019 19:17
    Published on: 
  39. Content Type:Research Article

    Dung beetle glycosaminoglycan is known to possess anti-aging activities. However, its anti-cancer mechanisms are not fully elucidated yet. The objective of this study was to evaluate the anti-cancer effect of ...
    Authors:Mi Young Ahn, Ban Ji Kim, Ha Jeong Kim, Jang Mi Jin, Hyung Joo Yoon, Jae Sam Hwang and Kun-Koo Park
    Citation:BMC Cancer 2019 19:9
    Published on: 
  40. Content Type:Research Article

    The GTPase KRas4B has been utilized as a principal target in the development of anticancer drugs. PDE6δ transports KRas4B to the plasma membrane, where it is released to activate various signaling pathways req...
    Authors:Diana Casique-Aguirre, Paola Briseño-Díaz, Ponciano García-Gutiérrez, Claudia Haydée González-de la Rosa, Reyna Sara Quintero-Barceinas, Arturo Rojo-Domínguez, Irene Vergara, Luis Alberto Medina, José Correa-Basurto, Martiniano Bello, Rosaura Hernández-Rivas, María del RocioThompson-Bonilla and Miguel Vargas
    Citation:BMC Cancer 2018 18:1299
    Published on: 
  41. Content Type:Research Article

    HDIL-2 is approved for advanced melanoma based on its durable antitumor activity. MAGE-A3 cancer immunotherapeutic (MAGE-A3 CI) is a recombinant MAGE-A3 protein combined with an immunostimulant adjuvant system...
    Authors:Jennifer L. McQuade, Jade Homsi, Carlos A. Torres-Cabala, Roland Bassett, Rashmi Murthy Popuri, Marihella L. James, Luis M. Vence and Wen-Jen Hwu
    Citation:BMC Cancer 2018 18:1274
    Published on: 
  42. Content Type:Research Article

    Brain tumor vasculature can be significantly compromised and leakier than that of normal brain blood vessels. Little is known if there are vascular permeability alterations in the brain adjacent to tumor (BAT)...
    Authors:Afroz S. Mohammad, Chris E. Adkins, Neal Shah, Rawaa Aljammal, Jessica I. G. Griffith, Rachel M. Tallman, Katherine L. Jarrell and Paul R. Lockman
    Citation:BMC Cancer 2018 18:1225
    Published on: 
  43. Content Type:Research Article

    In case of high grade non-muscle invasive bladder cancer (HG-NMIBC), intravesical BCG represents the first-line treatment; despite the “gold” standard therapy, up to 50% of patients relapse, needing radical cy...
    Authors:Marco Racioppi, Luca Di Gianfrancesco, Mauro Ragonese, Giuseppe Palermo, Emilio Sacco and Pier Francesco Bassi
    Citation:BMC Cancer 2018 18:1224
    Published on: 
  44. Content Type:Research Article

    Agarose encapsulated murine renal adenocarcinoma cells (RENCA macrobeads) are currently being investigated in clinical trials as a treatment for therapy-resistant metastatic colorectal cancer. We have previous...
    Authors:Prithy C. Martis, Atira T. Dudley, Melissa A. Bemrose, Hunter L. Gazda, Barry H. Smith and Lawrence S. Gazda
    Citation:BMC Cancer 2018 18:1217
    Published on: 
  45. Content Type:Research Article

    Glioblastoma multiforme (GBM) is the most malignant central nervous system tumor. Alkylating agent, temozolomide (TMZ), is currently the first-line chemotherapeutic agent for GBM. However, the sensitivity of G...
    Authors:Li Li, Yulun Huang, Yuge Gao, Tengfei Shi, Yunyun Xu, Huini Li, Marko Hyytiäinen, Jorma Keski-Oja, Qiuying Jiang, Yizhou Hu and Zhimin Du
    Citation:BMC Cancer 2018 18:1215
    Published on: 
  47. Content Type:Research Article

    The nudix family member enzyme MutT homologue-1 (MTH1) hydrolyses the oxidized nucleotides 8-oxo-dGTP and 2-hydroxy-dATP and thus prevents the incorporation of damaged nucleotides into nuclear and mitochondria...
    Authors:Mosche Pompsch, Julia Vogel, Fabian Classen, Philip Kranz, George Iliakis, Helena Riffkin, Ulf Brockmeier and Eric Metzen
    Citation:BMC Cancer 2018 18:1190
    Published on: 
  48. Content Type:Research Article

    Waixenicin A, a bioactive extract of soft coral Sarcothelia edmondsoni, has been shown to be anti-neoplastic. However, its mechanisms of action remain unclear. Cancer stem cells (CSCs) and associated stemness fac...
    Authors:Kai Liu, Shao-Hua Xu, Zhao Chen, Qing-Xin Zeng, Zhi-Jun Li and Zhou-Miao Chen
    Citation:BMC Cancer 2018 18:1167
    Published on: 
  49. Content Type:Research Article

    Insulin resistance (IR) is closely associated with the progression of hepatocellular carcinoma (HCC). Acyclic retinoid (ACR) targets retinoid X receptor α and reportedly prevents HCC recurrence in clinical pra...
    Authors:Norihisa Nishimura, Kosuke Kaji, Mitsuteru Kitade, Yosuke Aihara, Shinya Sato, Kenichiro Seki, Yasuhiko Sawada, Hiroaki Takaya, Yasushi Okura, Hideto Kawaratani, Kei Moriya, Tadashi Namisaki, Akira Mitoro and Hitoshi Yoshiji
    Citation:BMC Cancer 2018 18:1164
    Published on: 
  50. Content Type:Case Report

    Adults with relapsed acute lymphoblastic leukemia (ALL) have a poor prognosis, especially in patients who relapsed within 6 months of complete remission 1 (CR1). Allogeneic hematopoietic stem cell transplantat...
    Authors:Shupeng Wen, Zhiyun Niu, Lina Xing, Ying Wang, Hang Li, Na Kuang, Jianmin Luo, Xuejun Zhang and Fuxu Wang
    Citation:BMC Cancer 2018 18:1143
    Published on: 
Publicado por en

No hay comentarios:

Publicar un comentario

Suscribirse a: Enviar comentarios (Atom)